Back

Clinical impact of renal function changes in patients with atrial fibrillation receiving anticoagulation with marginal renal function

7 April 2024 (08:30 - 15:00)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation: stroke - oral anticoagulants Oral Anticoagulation EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Assistant Professor Kyung-Yeon Lee

Korea University Guro Hospital, Seoul (Korea (Republic of))

5 More presentations in this session

Presentation thumbnail
Genetic and clinical risk factors for stroke recurrence with different impact by assessment age: data from the UK Biobank
Doctor S. Chung (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants versus vitamin K antagonists as stroke prevention in atrial fibrillation after cardiac surgery: a systematic review and meta-analysis
Mr M. Terpstra (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Characteristics and incidence of peri-device leaks after left atrial appendage closure in patients with prior electrical isolation of left atrial appendage during catheter ablation
Doctor A. Maan (Toledo, US)
Abstract Slides Video
Presentation thumbnail
Predicting atrial fibrillation risk following embolic stroke of unknown source using cardiac magnetic resonance imaging
Doctor I. Kotadia (London, GB)
Abstract Slides Video
Presentation thumbnail
Impact of photoplethysmography-based smartphone rhythm monitoring on atrial fibrillation detection and management after cardiac surgery: a pragmatic randomized trial
Doctor H. Gruwez (Leuven, BE)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation: stroke - oral anticoagulants
Video

The Event

Event poster

EHRA 2024

7 April - 9 April 2024
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on stroke prevention in atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources